Clinical Overview
Clinical Features
In neonates two syndromes exist: early-onset (<7 days old) and late-onset (7-90 days old). Both include: sepsis, pneumonia and meningitis. In adults: sepsis and soft tissue infections. Pregnancy-related infections: sepsis, amnionitis, urinary tract infection, and stillbirth.
Etiologic Agent
Streptococcus agalactiae or group B Streptococcus (group B strep).
Incidence
Approximately 19,800 cases occur annually in the United States in all age groups; approximately 7,600 cases occurred in newborns before recent prevention. The rate of early-onset infection has decreased from 1.7 cases per 1,000 live births (1993) to 0.28 cases per 1,000 live births (2008). Since active prevention began in the mid 1990s, the rate of group B strep disease among newborns in the first week of life has declined by 80%. Racial disparities in disease persist with the incidence among blacks approximately twice that of non-blacks for all age groups.
Sequelae
Neurologic sequelae include sight or hearing loss and cerebral palsy. Death occurs in 5% of infants and 8% of adults.
Costs
Direct medical costs of neonatal disease before prevention were $294 million annually.
Transmission
Asymptomatic carriage in gastrointestinal and genital tracts is common. Intrapartum transmission via ascending spread from vagina occurs. Mode of transmission of disease in nonpregnant adults is unknown.
Risk Groups
Adults with chronic illnesses (e.g., diabetes mellitus and cardiovascular disease), pregnant women, the fetus, and the newborn are at risk. For neonatal disease, risk is higher among infants born to women with group B strep colonization, prolonged rupture of membranes or preterm delivery. Rates are substantially higher among blacks and the elderly.
Surveillance
Active surveillance for invasive group B strep disease is ongoing in a multistate population of approximately 33 million, including approximately 500,000 live births annually. The disease is not reportable in most states.
Trends
This pathogen emerged in the 1970s as the most common cause of sepsis in newborns. Adult disease was recognized more recently and the incidence has been increasing. Early-onset disease has declined by 80% since increased use of intrapartum prophylaxis has occurred.
Challenges
To implement universal screening in all prenatal health care settings by promoting use of CDC guidelines for prevention of group B strep. To monitor potential adverse consequences of increased use of antibiotics. To identify a strategy for prevention of late-onset disease and adult disease.
Activities
Interface with national organizations, health departments and community groups to create awareness and promote a universal screening policy in all prenatal care settings. Continued active surveillance by the Active Bacterial Core surveillance (ABCs) - to monitor rates of group B strep in 10 states in the country; this data can be used for continued research and to evaluate the effect of the newest guidelines.
Images and logos on this website which are trademarked/copyrighted or used with permission of the trademark/copyright or logo holder are not in the public domain. These images and logos have been licensed for or used with permission in the materials provided on this website. The materials in the form presented on this website may be used without seeking further permission. Any other use of trademarked/copyrighted images or logos requires permission from the trademark/copyright holder...more
This graphic notice means that you are leaving an HHS Web site. For more information, please see the Exit Notification and Disclaimer policy.
Contact Us:
- Centers for Disease Control and Prevention
1600 Clifton Rd
Atlanta, GA 30333 - 800-CDC-INFO
(800-232-4636)
TTY: (888) 232-6348 - New Hours of Operation
8am-8pm ET/Monday-Friday
Closed Holidays - cdcinfo@cdc.gov



